Lead Product(s) : GLPG2737
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company announced completion GLPG2737 trial a CFTR inhibitor in patients with ADPKD. Primary objectives of trial is to assess the effect on growth of total kidney volume over 52 weeks compared to placebo as well as overall safety and tolerability.
Product Name : GLPG2737
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2021
Lead Product(s) : GLPG2737
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable